Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.53 |
| ▸ | GSR | P00390 | 1/20 | 0.48 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.47 |
| ▸ | CPB2 | Q96IY4 | 12/20 | 0.45 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL209237 | 1.00 | FOLH1 (0.53) | FOLH1GSRRNPEPCPB2SLC6A5 | |
| SCHEMBL3727817 | 1.00 | FOLH1 (0.53) | FOLH1GSRRNPEPCPB2SLC6A5 | |
| SCHEMBL7027613 | 0.94 | FOLH1 (0.46) | FOLH1GSRRNPEPCPB2SLC6A5 | |
| SCHEMBL3725106 | 0.94 | FOLH1 (0.46) | FOLH1GSRRNPEPCPB2SLC6A5 | |
| SCHEMBL7027611 | 0.94 | FOLH1 (0.46) | FOLH1GSRRNPEPCPB2SLC6A5 | |
| SCHEMBL24764859 | 0.88 | FOLH1 (0.54) | FOLH1GSRRNPEPCPB2SLC6A5 | |
| SCHEMBL4951252 | 0.87 | GSR (0.52) | FOLH1GSRRNPEPCPB2SLC6A5 | |
| SCHEMBL1116199 | 0.87 | FOLH1 (0.51) | FOLH1GSRRNPEPCPB2SLC6A5 | |
| SCHEMBL5419504 | 0.87 | FOLH1 (0.51) | FOLH1GSRRNPEPCPB2SLC6A5 | |
| SCHEMBL23451044 | 0.87 | FOLH1 (0.51) | FOLH1GSRRNPEPCPB2SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 270 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3548512-B1 | USE OF PEPTIDE COMPOUNDS FOR PROMOTING SURVIVAL, GROWTH AND CELL DIFFERENTIATION | AXOLTIS PHARMA (FR) | 2023-08-02 | — | — | EP | claimed |
| EP-2427775-B1 | PEPTIDE LIGANDS OF SOMATOSTATIN RECEPTORS | BCN PEPTIDES SA (ES) | 2021-08-11 | — | — | EP | claimed |
| US-20200080053-A1 | USE OF PEPTIDE COMPOUNDS FOR PROMOTING SURVIVAL, GROWTH AND CELL DIFFERENTIATION | AXOLTIS PHARMA (FR) | 2020-03-12 | — | — | US | claimed |
| CN-110431149-A | Peptide compounds are used to promote the purposes of survival, growth and cell differentiation | AXOLTIS PHARMA | 2019-11-08 | — | — | CN | claimed |
| EP-3548512-A1 | USE OF PEPTIDE COMPOUNDS FOR PROMOTING SURVIVAL, GROWTH AND CELL DIFFERENTIATION | Axoltis Pharma (FR) | 2019-10-09 | — | — | EP | claimed |
| WO-2018104325-A1 | USE OF PEPTIDE COMPOUNDS FOR PROMOTING SURVIVAL, GROWTH AND CELL DIFFERENTIATION | NEURONAX SA (FR) | 2018-06-14 | — | — | WO | claimed |
| EP-3330284-A1 | USE OF PEPTIDE COMPOUNDS FOR PROMOTING SURVIVAL, GROWTH AND CELL DIFFERENTIATION | NEURONAX SA (FR) | 2018-06-06 | — | — | EP | claimed |
| US-20260048158-A1 | B7-H3 MINIPROTEINS, CONJUGATES, AND USES THEREOF | AKTIS ONCOLOGY INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-12427212-B2 | Nectin-4 binding miniproteins, conjugates and uses thereof | AKTIS ONCOLOGY, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20250242065-A1 | MINIPROTEINS, CONJUGATES & USES THEREOF | AKTIS ONCOLOGY, INC. | 2025-07-31 | — | — | US | disclosed |
| WO-2025122976-A1 | B7-H3 MINIPROTEINS, CONJUGATES, AND USES THEREOF | AKTIS ONCOLOGY, INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| WO-2025072791-A2 | MINIPROTEINS, CONJUGATES & USES THEREOF | AKTIS ONCOLOGY, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| US-12163154-B2 | Use of peptide compounds for promoting survival, growth and cell differentiation | AXOLTIS PHARMA (FR) | 2024-12-10 | — | — | US | disclosed |
| WO-1994018231-A1 | INHIBITION OF TRAUMA-INDUCED TUMOR GROWTH | BIOMEASURE, INC. (US) | 1994-08-18 | — | — | WO | disclosed |
| EP-0522152-A1 | LHRH ANTAGONISTS | THE ADMINISTRATORS OF THE TULANE UNIVERSITY EDUCATIONAL FUND (US) | 1993-01-13 | — | — | EP | disclosed |
| WO-1992013883-A1 | LHRH ANTAGONISTS | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 1992-08-20 | — | — | WO | disclosed |
| WO-1991019743-A2 | COMBINED TREATMENT WITH GnRH ANTAGONIST AND GnRH TO CONTROL GONADOTROPIN LEVELS IN MAMMALS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 1991-12-26 | — | — | WO | disclosed |
| EP-0377665-A1 | EFFECTIVE ANTAGONISTS OF THE LUTEINIZING HORMONE RELEASING HORMONE WHICH RELEASE NEGLIGIBLE HISTAMINE. | UNIV TEXAS (US) | 1990-07-18 | — | — | EP | disclosed |
| WO-1989009786-A1 | PEPTIDE DERIVATIVES | SANDOZ AG (CH) | 1989-10-19 | — | — | WO | disclosed |
| WO-1989001944-A1 | EFFECTIVE ANTAGONISTS OF THE LUTEINIZING HORMONE RELEASING HORMONE WHICH RELEASE NEGLIGIBLE HISTAMINE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1989-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250242065-A1 | MINIPROTEINS, CONJUGATES & USES THEREOF | NECTIN4, CD2BP2, HAVCR2 | FOLH1 422/4885GSR 4730/4885RNPEP 138/4885 |
| US-12427212-B2 | Nectin-4 binding miniproteins, conjugates and uses thereof | NECTIN4, CD2BP2, HAVCR2 | FOLH1 706/4885GSR 4839/4885RNPEP 398/4885 |
| US-20260048158-A1 | B7-H3 MINIPROTEINS, CONJUGATES, AND USES THEREOF | MICA, CD274, JMJD6 | FOLH1 1262/4885GSR 4457/4885RNPEP 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.